Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.53
+0.195014.66%
Volume:1.95M
Turnover:2.84M
Market Cap:126.54M
PE:-0.53
High:1.54
Open:1.38
Low:1.38
Close:1.33
Loading ...

Editas: Q4 Earnings Snapshot

Associated Press Finance
·
06 Mar

Editas Medicine Q4 2024 GAAP EPS $(0.55) Misses $(0.38) Estimate, Sales $30.604M Miss $32.230M Estimate

Benzinga
·
06 Mar

BRIEF-Editas Medicine Q4 Net Income USD -45.395 Million

Reuters
·
06 Mar

Editas Medicine Q4 EPS USD -0.55

THOMSON REUTERS
·
06 Mar

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

GlobeNewswire
·
06 Mar

Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
03 Mar

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

GlobeNewswire
·
24 Feb

Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
24 Feb

Bank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT)

TIPRANKS
·
16 Jan

Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements

TIPRANKS
·
15 Jan

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

TipRanks
·
14 Jan

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks
·
14 Jan

Editas Medicine announces strategic priorities, 2025 key milestones

TIPRANKS
·
13 Jan

Editas Medicine Inc - Has Operational Runway Into Q2 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Inc - to Submit at Least One Ind/Cta by 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Highlights New in Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-Year Strategic Priorities

THOMSON REUTERS
·
13 Jan

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Dow Jones
·
13 Jan

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks
·
16 Dec 2024